| |
HIV-1 TAT VACCINES: INTELLECTUAL PROPERTY |
|
|
 The intellectual property ownership for Tat vaccine candidates and microparticles rests with the Istituto Superiore di Sanità (ISS), the Italian National Institute of Health. |
|
| International patent applications have been filed to protect the following intellectual properties: |
|
- HIV-1 Tat for use as a preventive and therapeutic vaccine
Status: granted in countries of the European Patent Convention, Australia, New Zealand, Russia, Singapore; in advanced prosecution elsewhere
|
- HIV-1 Tat for use as an adjuvant and delivery vehicle for non-HIV antigens
Status: granted in New Zealand, Singapore, China; in advanced prosecution elsewhere
|
- HIV-1 Tat for use as a co-antigen in non-HIV vaccines
Status: national phase prosecution
|
- Novel Tat-Env complexes
Status: national phase prosecution
|
- Microparticles for antigen delivery
Status: national phase prosecution
|
- Nanoparticles for delivery of DNA/RNA-based therapeutics and vaccine antigens
Status: national phase prosecution
|
- Improved replication-competent adenoviral vectors
Status: national phase prosecution
|
- Manufacturing process for biologically active Tat
Status: national phase prosecution
|
|
